COVID-19 住院患者静脉血栓栓塞症的发生率、预后与实验室指标的系统综述与荟萃分析
该研究系统检索 PubMed、Embase、Cochrane Library、MedRxiv 和 BioRxiv,纳入 18 项回顾性、6 项前瞻性观察性和 2 项横断面研究,共 4382 例 COVID-19 住院患者,汇总 VTE 发生率、预后及实验室指标。结果显示 VTE 总发生率为 28.3%,重症患者为 38.0%,高于一般患者的 17.2%;重症合并 VTE 者死亡风险显著高于无 VTE 者(OR 2.02,95%CI 1.15-3.53,P=.014)。
要点
- COVID-19 住院患者 VTE 总发生率为 28.3%,重症患者达 38.0%。
- 重症 COVID-19 合并 VTE 者死亡风险显著高于无 VTE 者。
- D-二聚体升高可能提示 COVID-19 患者发生 VTE。
核心结论
- COVID-19 住院患者中 VTE、DVT 和肺栓塞发生率较高,重症患者尤为突出。
- 重症 COVID-19 合并 VTE 患者的死亡率显著高于无 VTE 者。
- D-二聚体升高可能是 COVID-19 患者发生 VTE 的提示指标。
研究设计与样本
- 系统综述与荟萃分析,按照 PRISMA 声明进行。
- 系统检索 PubMed、Embase、Cochrane Library、MedRxiv 和 BioRxiv。
- 纳入 18 项回顾性研究、6 项前瞻性观察性研究和 2 项横断面研究,共 4382 例 COVID-19 住院患者。
主要发现
- 男性患者显著多于女性(OR 1.59,95%CI 1.25-2.02,P<.001)。
- VTE 总发生率为 28.3%(95%CI 21.6%-35.4%),重症与一般患者分别为 38.0%(95%CI 29.1%-47.4%)和 17.2%(95%CI 11.4%-23.8%)。
- 下肢 DVT 总发生率为 18.3%(95%CI 10.8%-27.2%),重症与一般患者分别为 22.1%(95%CI 11.0%-35.5%)和 12.8%(95%CI 5.0%-23.3%)。
- 肺栓塞总发生率为 17.6%(95%CI 12.3%-23.5%),重症与一般患者分别为 21.7%(95%CI 14.8%-29.3%)和 12.5%(95%CI 6.1%-23.5%)。
- COVID-19 严重程度未分类时,VTE 患者死亡率 25.2%(95%CI 12.2%-40.5%)与非 VTE 患者 10.2%(95%CI 3.4%-19.5%)差异无统计学意义(OR 1.88,95%CI 0.46-7.64,P=.377)。
关键数值与推荐
- 重症 COVID-19 合并 VTE 者较无 VTE 者死亡风险显著升高(OR 2.02,95%CI 1.15-3.53,P=.014)。
- 多项研究中 COVID-19 合并 VTE 患者的 D-二聚体水平显著高于无 VTE 者。
临床怎么用
- 对 COVID-19 住院患者应关注 VTE 风险,重症患者风险更高。
- D-二聚体升高可作为提示 VTE 发生的实验室线索。
- 重症 COVID-19 合并 VTE 提示预后更差,需加强监测与评估。
局限性
- 纳入研究以回顾性和观察性设计为主,可能存在异质性与偏倚。
- 部分分析中 COVID-19 严重程度未分类,影响死亡率比较的解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We have summarized the incidence, anticoagulation panels, laboratory characteristics, and mortality of venous thromboembolism (VTE) in hospitalized patients with coronavirus disease 2019 (COVID-19). METHODS: After systematically searching PubMed, Embase, the Cochrane Library, MedRxiv, and BioRxiv, a systematic review and meta-analysis of 18 retrospective, 6 prospective observational, and 2 cross-sectional studies was performed according to the guidelines of the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement. RESULTS: Overall, 4382 hospitalized patients with COVID-19 were included. Men accounted for significantly more patients than did women (odds ratio [OR], 1.59; 95% confidence interval [CI], 1.25-2.02; P < .001). The total incidence of VTE among the patients with COVID-19 was 28.3% (95% CI, 21.6%-35.4%), with an incidence of 38.0% (95% CI, 29.1%-47.4%) and 17.2% (95% CI, 11.4%-23.8%) among those with severe and general COVID-19, respectively. The total incidence of deep vein thrombosis (DVT) of the lower extremities was 18.3% (95% CI, 10.8%-27.2%). The incidence of DVT was 22.1% (95% CI, 11.0%-35.5%) and 12.8% (95% CI, 5.0%-23.3%) in those with severe and general COVID-19, respectively. The total incidence of pulmonary embolism was 17.6% (95% CI, 12.3%-23.5%), with a rate of 21.7% (95% CI, 14.8%-29.3%) in severe cases and 12.5% (95% CI, 6.1%-23.5%) in general cases. When COVID-19 severity was unclassified, the mortality for the patients with VTE was not significantly greater (25.2%; 95% CI, 12.2%-40.5%) than that for those without VTE (10.2%; 95% CI, 3.4%-19.5%; OR, 1.88; 95% CI, 0.46-7.64; P = .377). However, among the patients with severe COVID-19, those who had developed VTE had significantly greater mortality compared with those without VTE (OR, 2.02; 95% CI, 1.15-3.53; P = .014). The patients with COVID-19 and VTE had significantly higher D-dimer levels than did similar patients without VTE in multiple studies. CONCLUSIONS: The occurrence of VTE, DVT, and pulmonary embolism has been substantial among hospitalized patients with COVID-19, especially among those with severe COVID-19. Patients with severe COVID-19 and VTE had significantly greater mortality compared with similar patients without VTE. An increased D-dimer level might be an indicator of the occurrence of VTE in patients with COVID-19.
引用
- Liu Y, Cai J, Wang C, et al. A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33529719. doi:10.1016/j.jvsv.2021.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。